SCHEMBL18101485

SCHEMBL18101485

CC(C)(F)CN1CCC(F)(CNC(=O)c2cc(Cl)c(N)c3cccnc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 2/20 0.48
HTR3B O95264 2/20 0.48
HTR3A P46098 2/20 0.48
HTR3D Q70Z44 2/20 0.48
HTR3C Q8WXA8 2/20 0.48
KCNH2 Q12809 2/20 0.41
DYRK1A Q13627 3/20 0.38
WNT1 P04628 2/20 0.38
SLC6A9 P48067 7/20 0.36
HTR1A P08908 2/20 0.35
ADRA1A P35348 2/20 0.35
DRD2 P14416 1/20 0.35
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16102963 0.93 HTR3E (0.48) HTR3EHTR3BHTR3AHTR3DHTR3C
Hydrochloric Acid SCHEMBL16097867 0.92 HTR3E (0.47) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18094608 0.91 HTR3E (0.46) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18094593 0.90 HTR3E (0.45) HTR3EHTR3BHTR3AHTR3DHTR3C
Fumaric Acid SCHEMBL16097773 0.89 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
Fumaric Acid SCHEMBL16102007 0.89 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16102006 0.88 HTR3E (0.44) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16102974 0.85 HTR3E (0.47) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL18094618 0.84 KCNH2 (0.38) HTR3EHTR3BHTR3AHTR3DHTR3C
SCHEMBL16123528 0.84 KCNH2 (0.38) HTR3EHTR3BHTR3AHTR3DHTR3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790211-B2 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists SUVEN LIFE SCIENCES LIMITED (IN) 2017-10-17 US claimed
EP-2976337-B1 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS SUVEN LIFE SCIENCES LTD (IN) 2018-05-02 EP disclosed
EP-2976337-B1 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS SUVEN LIFE SCIENCES LTD (IN) 2018-05-02 EP disclosed
US-9790211-B2 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists SUVEN LIFE SCIENCES LIMITED (IN) 2017-10-17 US disclosed
US-9790211-B2 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists SUVEN LIFE SCIENCES LIMITED (IN) 2017-10-17 US disclosed
US-20160280694-A1 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS SUVEN LIFE SCIENCES LIMITED (IN) 2016-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280694-A1 5-AMINO-QUINOLINE-8-CARBOXAMIDE DERIVATIVES AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A HTR3E 18/4885HTR3B 6/4885HTR3A 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.